• Open Access
    • Comment cela fonctionne?
    • Ouvrir une session
    • Contact

    Voir le document

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Voir le document 
    • Accueil de LUCK
    • HE Bruxelles-Brabant
    • HE2B - HE
    • Santé
    • Voir le document
    • Accueil de LUCK
    • HE Bruxelles-Brabant
    • HE2B - HE
    • Santé
    • Voir le document
    Voir/Ouvrir
    Article principal (1.149Mo)
    Date
    2016-02-16
    Auteur
    Vallée, Nicolas
    LAMBRECHTS, Kate
    De Maistre, Sébastien
    Royal, Perrine
    Mazella, Jean
    Borsotto, Marc
    Heurteaux, Catherine
    Abraini, Jacques
    RIsso, Jean-Jacques
    Blatteau, Jean-Eric
    Metadata
    Afficher la notice complète
    Partage ça

    Fluoxetine Protection in Decompression Sickness in Mice is Enhanced by Blocking TREK-1 Potassium Channel with the "spadin" Antidepressant

    Résumé
    In mice, disseminated coagulation, inflammation, and ischemia induce neurological damage that can lead to death. These symptoms result from circulating bubbles generated by a pathogenic decompression. Acute fluoxetine treatment or the presence of the TREK-1 potassium channel increases the survival rate when mice are subjected to an experimental dive/decompression protocol. This is a paradox because fluoxetine is a blocker of TREK-1 channels. First, we studied the effects of an acute dose of fluoxetine (50 mg/kg) in wild-type (WT) and TREK-1 deficient mice (knockout homozygous KO and heterozygous HET). Then, we combined the same fluoxetine treatment with a 5-day treatment protocol with spadin, in order to specifically block TREK-1 activity (KO-like mice). KO and KO-like mice were regarded as antidepressed models. In total, 167 mice (45 WTcont 46 WTflux 30 HETflux and 46 KOflux) constituting the flux-pool and 113 supplementary mice (27 KO-like 24 WTflux2 24 KO-likeflux 21 WTcont2 17 WTno dive) constituting the spad-pool were included in this study. Only 7% of KO-TREK-1 treated with fluoxetine (KOflux) and 4% of mice treated with both spadin and fluoxetine (KO-likeflux) died from decompression sickness (DCS) symptoms. These values are much lower than those of WT control (62%) or KO-like mice (41%). After the decompression protocol, mice showed significant consumption of their circulating platelets and leukocytes. Spadin antidepressed mice were more likely to exhibit DCS. Nevertheless, mice which had both blocked TREK-1 channels and fluoxetine treatment were better protected against DCS. We conclude that the protective effect of such an acute dose of fluoxetine is enhanced when TREK-1 is inhibited. We confirmed that antidepressed models may have worse DCS outcomes, but concomitant fluoxetine treatment not only decreased DCS severity but increased the survival rate.

    Parcourir

    Tout LUCKCommunautés & CollectionsAuteurTitreDate de publicationSujetType de documentTitre de périodiqueThématiqueCette collectionAuteurTitreDate de publicationSujetType de documentTitre de périodiqueThématique

    Mon compte

    Ouvrir une sessionS'inscrire

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Plan du site

    • Open Access
    • Comment cela fonctionne?
    • Mon compte

    Contact

    • L’équipe de LUCK
    • Synhera
    • CIC